
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is shaping up to be a strong player in the biotechnology landscape, with a promising lead program in NBTXR3, a unique physics-based approach to treating cancer that has shown positive results in clinical studies. The company also has a lucrative collaboration with JNJ for the development and commercialization of NBTXR3, providing a potential stream of royalties and milestones. While there are potential clinical and commercial risks, the data and collaboration support a positive outlook for Nanobiotix's stock.
Bears say
Nanobiotix is currently in a strong financial position with a cash runway lasting until 2029, but faces significant risks due to the early stage of its pipeline and the highly novel nature of its lead program, NBTXR3. Downside risks include potential clinical trial failures, safety concerns, regulatory setbacks, and challenges with commercial performance post-approval. Additionally, the company's recent focus on its Curadigm platform could also pose challenges with commercialization.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares